drugset / Trial / NCT06319469
The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention
RandomizedParallel-groupOpen-labelTreatment
Summary
Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely. This study aims to evaluate whether pyridostigmine bromide added to silodosin is beneficial in treating acute urine retention caused by BPH.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridostigmine | Small molecule | 60 mg | — |
| Subject | Silodosin | Unknown | 8 mg | — |